lilly tirzepatide releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly's next-gen drug shows significant

Interim results published by Jastreboff et al

The MELK inhibitor OTSSP167 protects intestinal epithelial cells by maintaining a normal composition of gut microbiota and balancing gut microbiota distribution, inhibiting ferroptosis, reducing the expression of pro-inflammatory factors in intestinal tissues, and suppressing the AKT/IKK/P65 and ERK/IKK/P65 signaling cascades in vitro and in vivo, thereby exerting a protective effect on the intestinal tissues of colitis mice [291, 292]

The main studies of both clinical programs are detailed below

Structure meals around 30-40 grams of protein, abundant vegetables providing fiber, and moderate healthy fats

How to manage it: Eat smaller, more frequent meals

Due to its significant weight loss effects, tirzepatide has also shown potential in managing conditions like non-alcoholic fatty liver disease (NAFLD), though further research is necessary (43)(46)